fda approval status of ghk-cu FDA's Overreach on Compounded Peptides The FDA panel will review

I'll update my position if strong human trial data emerges

In several preclinical studies, BPC157 reduced the severity of gut injuries, reversed damage from NSAIDs, and even supported nerve regeneration

Experiences vary from person to person

Its sold as a research chemical or supplement in most countries, intended for research purposes only. This regulatory gray area means: Quality control varies significantly between suppliers Purity and actual peptide content may not match labels No official medical oversight or standardized protocols exist It cannot legally be marketed for treating or preventing any medical condition This regulatory status reflects the current state of peptide research generallymany promising compounds exist in this space between laboratory research and approved therapeutic use